Here’s a shocking revelation: the shingles vaccine might not only shield you from a painful viral outbreak but could also be a game-changer in the fight against dementia. And this is the part most people miss—it might even help treat it. Recent research from Stanford University and other institutions has uncovered something truly groundbreaking. When Wales introduced the shingles vaccine over a decade ago, scientists noticed something remarkable: not only did it reduce the risk of developing dementia, but it also lowered the chances of dying from it for those already diagnosed. This suggests that boosting your immunity to shingles could have a broader protective effect on cognitive health.
In their study, published in Cell, the researchers boldly stated, ‘This study suggests that [shingles] vaccination slows or prevents disease progression across the entire disease course of dementia.’ But how did they arrive at such a conclusion? But here’s where it gets controversial—they leveraged a natural experiment that occurred in Wales in 2013. When the shingles vaccination program began, it had strict age restrictions: only those born on or after September 2, 1933, were eligible. This clear cutoff, combined with the UK’s meticulous record-keeping, allowed researchers to compare dementia rates in similar groups of older adults before and after the vaccine’s introduction, using the ineligible group as a control.
In a previous study, they found that vaccinated individuals were 20% less likely to be diagnosed with dementia over seven years. But this time, they dug deeper. They wanted to know if the vaccine’s benefits extended to different stages of dementia. Using the same method, they discovered that vaccinated individuals were less likely to develop mild cognitive impairment (MCI), often the earliest stage of dementia. Even more striking, among those already diagnosed with dementia, vaccinated individuals were less likely to die from the condition.
‘That means the vaccine doesn’t just have preventive potential, but actual therapeutic potential as a treatment,’ explained Pascal Geldsetzer, the study’s senior author. ‘To me, this was really exciting and unexpected.’ But here’s the kicker—while these findings are compelling, they don’t definitively prove causation. Yet, the researchers’ unique approach sidesteps many limitations of observational studies, adding weight to the growing evidence that the shingles vaccine offers more health benefits than we initially thought.
For instance, a study from last October revealed that vaccinated individuals are also less likely to develop heart disease or stroke and have a lower risk of premature death. Shingles is already notorious for being one of the most agonizing conditions a person can endure, and the vaccine is universally recommended for Americans starting at age 50. Now, with the added potential to protect your brain and heart, there’s even more reason to roll up your sleeve for this two-dose vaccine.
But what do you think? Is the shingles vaccine’s potential role in dementia prevention and treatment a medical breakthrough, or is it too early to draw such conclusions? Let’s spark a conversation—share your thoughts in the comments below!
